Combination Treatment with Octreotide Shows Improved Results in Tumors Associated with Carcinoid Syndrome
MD Anderson News Release 11/29/11
Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The...
Incoming 16 Will Join Efforts to Support Institution's Mission to Eradicate Cancer
MD Anderson News Release 11/28/...
Organization focuses academic, private sector strengths on process in dire need of improvement
MD Anderson News Release...
Many Men Discontinue Treatment, Increasing Their Chances for Recurrence
MD Anderson News Release 11/16/11
PODCAST: Listen to Dr. Sharon Giordanodiscuss male breast cancer, a disease
that is rare but increasing in incidence.
About half of male breast cancer patients who take the drug tamoxifen to prevent their disease from returning report side effects such as weight gain and sexual dysfunction, which...
Luncheon Honoring Cokie Roberts, Sam Donaldson Benefits Cancer Research, Patient Care
MD Anderson News Release 11/11/11...
MD Anderson News Release 11/10/11
When given alongside radiation therapy for head and neck cancer, acupuncture has shown for the first...
Targeted approach provides a new avenue for potential anti-obesity medication
MD Anderson News Release 11/9/11
...
Implications seen for fastest growing segment of cancer population
MD Anderson News Release 11/07/11
The survival...
UT MD Anderson experts share portion control Thanksgiving infographic
MD Anderson News Release 11/07/11
Adults...
Findings point to possible personalized brain tumor therapy with Src inhibitors
MD Anderson News Release 11/06/11...